Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,901,541
  • Shares Outstanding, K 177,990
  • Annual Sales, $ 114,620 K
  • Annual Income, $ -440,670 K
  • 60-Month Beta 1.94
  • Price/Sales 34.29
  • Price/Cash Flow N/A
  • Price/Book 3.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.69
  • Number of Estimates 7
  • High Estimate -0.64
  • Low Estimate -0.74
  • Prior Year -0.63
  • Growth Rate Est. (year over year) -9.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.43 +1.49%
on 08/05/20
25.06 -13.21%
on 07/09/20
-1.77 (-7.53%)
since 07/02/20
3-Month
19.24 +13.05%
on 05/06/20
25.06 -13.21%
on 07/09/20
+2.27 (+11.65%)
since 05/05/20
52-Week
13.63 +59.57%
on 03/16/20
29.99 -27.48%
on 08/08/19
-7.05 (-24.48%)
since 08/05/19

Most Recent Stories

More News
Nektar to Announce Financial Results for the Second Quarter 2020 on Thursday, August 6, 2020, After Close of U.S.-Based Financial Markets

, /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2020 on , after the close of U.S.-based financial markets. , President and Chief Executive...

NKTR : 21.75 (-0.78%)
Uptrend Call Working As Nektar Therapeut Stock Rises 28.4% (NKTR)

SmarTrend identified an Uptrend for Nektar Therapeut (NASDAQ:NKTR) on April 14th, 2020 at $19.16. In approximately 3 months, Nektar Therapeut has returned 28.39% as of today's recent price of $24.60.

NKTR : 21.75 (-0.78%)
Nektar Therapeut Falls 2.18% on Heavy Volume: Watch For Potential Rebound

Nektar Therapeut (NASDAQ:NKTR) traded in a range yesterday that spanned from a low of $22.74 to a high of $23.36. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of...

NKTR : 21.75 (-0.78%)
SmarTrend Watching for Potential Pullback in Shares of Nektar Therapeut After 1.64% Gain

Nektar Therapeut (NASDAQ:NKTR) traded in a range yesterday that spanned from a low of $21.34 to a high of $21.69. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high...

NKTR : 21.75 (-0.78%)
Nektar Therapeut Up 17.4% Since SmarTrend Uptrend Call (NKTR)

SmarTrend identified an Uptrend for Nektar Therapeut (NASDAQ:NKTR) on April 14th, 2020 at $19.16. In approximately 2 months, Nektar Therapeut has returned 17.38% as of today's recent price of $22.49.

NKTR : 21.75 (-0.78%)
Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)

, /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced the presentation of results from the Phase study evaluating multiple ascending doses of NKTR-358, a first-in-class T regulatory cell...

NKTR : 21.75 (-0.78%)
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology (EULAR 2020)

, /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it will webcast an analyst and investor conference call on at during EULAR 2020. The event will follow Thursday's virtual poster...

NKTR : 21.75 (-0.78%)
Nektar Therapeut Has Returned 17.6% Since SmarTrend Recommendation (NKTR)

SmarTrend identified an Uptrend for Nektar Therapeut (NASDAQ:NKTR) on April 14th, 2020 at $19.16. In approximately 1 month, Nektar Therapeut has returned 17.59% as of today's recent price of $22.53.

NKTR : 21.75 (-0.78%)
Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal

, /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of Phase 1 clinical data for its lead immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) in combination...

NKTR : 21.75 (-0.78%)
Nektar's (NKTR) Q1 Earnings and Revenues Top Estimates

Nektar (NKTR) reports encouraging first-quarter 2020 results. The company continues to progress with its pipeline candidates.

PFE : 38.45 (+0.16%)
MRK : 81.64 (-0.04%)
BMY : 59.69 (+0.37%)
NKTR : 21.75 (-0.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade NKTR with:

Business Summary

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists...

See More

Key Turning Points

2nd Resistance Point 22.39
1st Resistance Point 22.07
Last Price 21.75
1st Support Level 21.43
2nd Support Level 21.11

See More

52-Week High 29.99
Fibonacci 61.8% 23.74
Fibonacci 50% 21.81
Last Price 21.75
Fibonacci 38.2% 19.88
52-Week Low 13.63

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar